Screening recommendations for the identification of precursors and prevention of cervical cancer. Risk-based Management Guidelines for the abnormal screening results, including post-colposcopy or post-treatment scenarios.

In summary, providers caring for patients with elevated risk of anal cancer (lower genital tract dysplasia, HIV, etc.) should offer routine annual digital anal rectal exam (DARE). Providers should offer anal cytology and/or high-risk HPV testing if there is availability of referral to HRA for abnormal results.

In a patient with immunosuppression, screening should begin within 1 year of the onset of sexual activity or within the year of the diagnosis of HIV if already sexually active. Screening may be recommended more frequently.

2022年3月25日 · Consistent with American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines Perkins, et al. 2020, cervical cancer screening in patients <30 years old with HIV who have a cervix should begin within at least 2 years of first receptive sexual activity or by age 21 years Keller, et al. 2012.

2015年11月11日 · ASCCP Algorithms •Available at ASCCP website (free), also as an app ($9.99) - http://www.asccp.org/Portals/9/docs/ASCCP%20Management%20Gui delines_August%202014.pdf •Not specifically for women with HIV, but very similar to the OI Guidelines now with exception of ASCUS and LSIL www.asccp.org

This Research Letter summarizes all updates to the 2019 guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of HPV testing alone for patients undergoing observation for CIN2; revision of unsatisfactory cytology management; clarificat...

Read the ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The updated management guidelines aim to: Allow for a more complete and precise estimation of risk; Provide more appropriate intervention for high-risk individuals ; Recommend less intervention for low-risk individuals

2024年11月8日 · 2025年美国阴道镜和宫颈病理学会 (ASCCP)年度肛门生殖器和HPV相关疾病科学会议将于2025年4月24-26日在美国圣迭戈举行。 ASCCP年会是一个跨学科会议，汇集了来自妇产科、家庭医学、肿瘤学、病理学、内科和皮肤病学领域的医疗保健专业人士，届时来自世界各地的同行将探讨新的ASCCP基于风险的管理共识指南，HPV疫苗接种的创新方法以及服务 医疗条件薄弱人 群的全球战略。 ASCCP年会主题将涵盖宫颈癌筛查和管理的新方向，包括创新技术、外 …

2024年1月1日 · This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision ...

2024年7月9日 · Positive HPV screening tests are several-fold more common in women with HIV than in the general population, and as many as 16% of women with HIV have abnormal cervical cytology with ASC-US or worse at each clinical visit. 124 This often leads to repeated colposcopy and biopsy, although most of these colposcopies and biopsies in people with HIV ...